search
Back to results

PillCam Colon Capsule 2® (PCC2) in the Setting of Colorectal Cancer Screening Program

Primary Purpose

Colon Cancer

Status
Unknown status
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Capsule colonoscopy;
Sponsored by
Valduce Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Colon Cancer

Eligibility Criteria

50 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • asymptomatic average risk subjects, participating the regional colon cancer screening program, with positive iFOBT referred for colonoscopy

Exclusion Criteria:

  • presence of obstructive symptoms
  • swallowing disorders
  • presence of cardiac pacemaker

Sites / Locations

  • Ospedale ValduceRecruiting

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Diagnosis of CRC

Arm Description

All the patients enrolled received all the 3 procedures: capsule colonoscopy; CT-colonography and optical colonoscopy.

Outcomes

Primary Outcome Measures

Sensitivity of PillCam Colon Capsule 2 (R) in identifying significant colonic polyps
The number, size and location of significant polyps (>6mm) identified by each procedure were compared with the reference standard (RS), which was represented by the segmental unblinded colonoscopy.

Secondary Outcome Measures

to evaluate the tolerability of PCC2 as compared to optical colonoscopy (OC) and CT-colonography (CTC).
In order to evaluate the tolerability, each subject was asked to identify, among the 3 procedures performed, which was the less tolerated one and which one he would be willing to repeat.

Full Information

First Posted
December 3, 2012
Last Updated
December 5, 2012
Sponsor
Valduce Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT01744509
Brief Title
PillCam Colon Capsule 2® (PCC2) in the Setting of Colorectal Cancer Screening Program
Official Title
PillCam Colon Capsule 2® (PCC2) in the Setting of Colorectal Cancer Screening (CRC) Program: Comparison With a New Integrated Reference Standard
Study Type
Interventional

2. Study Status

Record Verification Date
December 2012
Overall Recruitment Status
Unknown status
Study Start Date
March 2011 (undefined)
Primary Completion Date
April 2013 (Anticipated)
Study Completion Date
April 2013 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Valduce Hospital

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
In this study the investigators evaluate the sensitivity of PCC2 (PillCam Colon Capsule 2 (R)) in identifying significant polyps in a CRC (Colo Recatal Cancer) screening program (primary outcome measure). Each enrolled patient underwent three procedures: colon capsule endoscopy, CT-colonography and optical colonoscopy. In this study the reference standard is represented by the segmental unblinded colonoscopy (the unblinding is based on results of both capsule endoscopy and Ct colonography) The investigators also evaluated the tolerability of PCC2 as compared to optical colonoscopy (OC) and CT-colonography (CTC).
Detailed Description
Asymptomatic average risk subjects with positive iFOBT (immunochemical Fecal Occult Blood Test), participating the regional screening program, were offered to undergo PCC2 (PillCam Colon Capsule 2 (R)) followed, 21 days later, by CTC and OC performed on the same day. The number, size and location of significant polyps (>6mm) identified by each procedure were compared with the reference standard (RS), which was represented by the segmental unblinded colonoscopy. The unblinding was based on the integration of CTC and PCC2 results. For the PPC2 the quality of the bowel preparation (adequate/inadequate) and the completeness of the examination (capsule excreted still working or visualization of the anal verge) were also reported. In order to evaluate the tolerability, each subject was asked to identify, among the 3 procedures performed, which was the less tolerated one and which one he would be willing to repeat.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colon Cancer

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
Outcomes Assessor
Allocation
N/A
Enrollment
35 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Diagnosis of CRC
Arm Type
Other
Arm Description
All the patients enrolled received all the 3 procedures: capsule colonoscopy; CT-colonography and optical colonoscopy.
Intervention Type
Device
Intervention Name(s)
Capsule colonoscopy;
Other Intervention Name(s)
Capsule colonoscopy: PillCam Coln Capsule 2
Intervention Description
All the enrolled patients underwent all the three study procedures; the colon capsule is the intervention under evaluation; the other 2 procedures (Ct colonography and optcal colonoscopy contribute to build the composite reference standard)
Primary Outcome Measure Information:
Title
Sensitivity of PillCam Colon Capsule 2 (R) in identifying significant colonic polyps
Description
The number, size and location of significant polyps (>6mm) identified by each procedure were compared with the reference standard (RS), which was represented by the segmental unblinded colonoscopy.
Time Frame
participants are followed for about 1 month
Secondary Outcome Measure Information:
Title
to evaluate the tolerability of PCC2 as compared to optical colonoscopy (OC) and CT-colonography (CTC).
Description
In order to evaluate the tolerability, each subject was asked to identify, among the 3 procedures performed, which was the less tolerated one and which one he would be willing to repeat.
Time Frame
participants are followed for about 1 month

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: asymptomatic average risk subjects, participating the regional colon cancer screening program, with positive iFOBT referred for colonoscopy Exclusion Criteria: presence of obstructive symptoms swallowing disorders presence of cardiac pacemaker
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Giancarlo Spinzi
Organizational Affiliation
Gastroenterology Unit; Ospedale Valduce
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ospedale Valduce
City
Como
ZIP/Postal Code
22100
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Giancarlo Spinzi, MD
Phone
0039031324145
Email
gispinz@tin.it
First Name & Middle Initial & Last Name & Degree
Giancarlo Spinzi, MD
First Name & Middle Initial & Last Name & Degree
Emanuele Rondonotti, MD
First Name & Middle Initial & Last Name & Degree
Vittorio Terruzzi
First Name & Middle Initial & Last Name & Degree
Franco Radaelli
First Name & Middle Initial & Last Name & Degree
Silvia Paggi
First Name & Middle Initial & Last Name & Degree
Arnaldo Amato
First Name & Middle Initial & Last Name & Degree
Giovanna Mandelli
First Name & Middle Initial & Last Name & Degree
Natalia Terreni
First Name & Middle Initial & Last Name & Degree
Lenoci Nicoletta
First Name & Middle Initial & Last Name & Degree
Gianni Imperiali
First Name & Middle Initial & Last Name & Degree
Claudia Borghi
First Name & Middle Initial & Last Name & Degree
Alberto Martegani

12. IPD Sharing Statement

Citations:
PubMed Identifier
24398064
Citation
Rondonotti E, Borghi C, Mandelli G, Radaelli F, Paggi S, Amato A, Imperiali G, Terreni N, Lenoci N, Terruzzi V, Baccarin A, Martegani A, Spinzi G. Accuracy of capsule colonoscopy and computed tomographic colonography in individuals with positive results from the fecal occult blood test. Clin Gastroenterol Hepatol. 2014 Aug;12(8):1303-10. doi: 10.1016/j.cgh.2013.12.027. Epub 2014 Jan 5.
Results Reference
derived

Learn more about this trial

PillCam Colon Capsule 2® (PCC2) in the Setting of Colorectal Cancer Screening Program

We'll reach out to this number within 24 hrs